| UniProt ID | VMAT2_HUMAN | |
|---|---|---|
| UniProt AC | Q05940 | |
| Protein Name | Synaptic vesicular amine transporter | |
| Gene Name | SLC18A2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 514 | |
| Subcellular Localization |
Cytoplasmic vesicle membrane Multi-pass membrane protein. |
|
| Protein Description | Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.. | |
| Protein Sequence | MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVPIIPSYLYSIKHEKNATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMFAFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILIAAGSICFANMGIAMLEPALPIWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMGRWLCALLGMIIVGVSILCIPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVSVYGSVYAIADVAFCMGYAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPAKEEKMAILMDHNCPIKTKMYTQNNIQSYPIGEDEESESD | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 15 | Phosphorylation | LVRWLQESRRSRKLI HHHHHHHHHHHHHHH | 21.74 | - | |
| 18 | Phosphorylation | WLQESRRSRKLILFI HHHHHHHHHHHHHHH | 32.43 | - | |
| 50 | Phosphorylation | IIPSYLYSIKHEKNA CCHHHHHHHCCCCCC | 23.67 | 24719451 | |
| 84 | N-linked_Glycosylation | SIFSYYDNSTMVTGN HHHHCCCCCCEEECC | 24.21 | UniProtKB CARBOHYD | |
| 91 | N-linked_Glycosylation | NSTMVTGNATRDLTL CCCEEECCCCCCEEE | 28.86 | UniProtKB CARBOHYD | |
| 111 | Phosphorylation | QHMVTNASAVPSDCP CHHHHCCCCCCCCCC | 31.69 | 22210691 | |
| 119 | Phosphorylation | AVPSDCPSEDKDLLN CCCCCCCCCCHHHCC | 65.83 | 22210691 | |
| 240 | Phosphorylation | LVGPPFGSVLYEFVG CCCCCCHHHHHHHHC | 14.88 | 22817900 | |
| 279 | Phosphorylation | PSRVQPESQKGTPLT HHHCCCCCCCCCCCH | 43.82 | - | |
| 283 | Phosphorylation | QPESQKGTPLTTLLK CCCCCCCCCCHHHHC | 23.35 | - | |
| 286 | Phosphorylation | SQKGTPLTTLLKDPY CCCCCCCHHHHCCCE | 19.32 | - | |
| 287 | Phosphorylation | QKGTPLTTLLKDPYI CCCCCCHHHHCCCEE | 37.46 | - | |
| 479 | Acetylation | SPPAKEEKMAILMDH CCCCHHHHHHHCCCC | 34.42 | 25953088 | |
| 511 | Phosphorylation | PIGEDEESESD---- CCCCCCCCCCC---- | 40.11 | 28270605 | |
| 513 | Phosphorylation | GEDEESESD------ CCCCCCCCC------ | 58.88 | 28270605 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 15 | S | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
| 18 | S | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
| 511 | S | Phosphorylation | Kinase | CK1-FAMILY | - | GPS |
| 511 | S | Phosphorylation | Kinase | CK2-FAMILY | - | GPS |
| 511 | S | Phosphorylation | Kinase | CK1_GROUP | - | PhosphoELM |
| 511 | S | Phosphorylation | Kinase | CK2_GROUP | - | PhosphoELM |
| 513 | S | Phosphorylation | Kinase | CK1-FAMILY | - | GPS |
| 513 | S | Phosphorylation | Kinase | CK2-FAMILY | - | GPS |
| 513 | S | Phosphorylation | Kinase | CK1_GROUP | - | PhosphoELM |
| 513 | S | Phosphorylation | Kinase | CK2_GROUP | - | PhosphoELM |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of VMAT2_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of VMAT2_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
Oops, there are no PPI records of VMAT2_HUMAN !! | ||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| D00197 | Reserpine (JP16/USP/INN); Apoplon (TN); Serpalan (TN) | |||||
| D08575 | Tetrabenazine (JAN/INN); Nitoman (TN); Xenazine (TN) | |||||
| D10170 | Tedatioxetine (USAN) | |||||
| D10171 | Tedatioxetine hydrobromide (USAN) | |||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-240, AND MASSSPECTROMETRY. | |
| "Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511 AND SER-513, ANDMASS SPECTROMETRY. | |